Stock listing

Frankfurt:51B Bioventix PLC Aktie

German listing (Frankfurt) of Bioventix PLC · home listing LSE:BVXP

Follow Bioventix PLC into a list and get an email when it puts out news.

Share price · FWB:51B

€22.40 EUR -0.20 (-0.9%)

Close on Nov 20, 2026

Past year -1.1% · daily closes, Nov 20, 2025 – Nov 6, 2026, adjusted for splits
Day range
€22.40 – €23.80 EURNov 20, 2026
Market cap
€117.0M EURAt the close on Nov 20, 2026 · price × 5.22M shares outstanding
52-week range
€15.02 – €23.80 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€257 EURMedian day 0 shares · 52 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026
Bioventix PLC logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
LSE:BVXP · Home1,950.00p GBX (pence)0.00 (0.0%)9,8921,950.00p1,995.00p1,850.00p1,950.00pClose on Nov 20, 2026
Frankfurt:51B€22.40 EUR-0.20 (-0.9%)—€22.40€23.80€22.40€22.60Close on Nov 20, 2026
Stuttgart:51B€22.40 EUR0.00 (0.0%)—€22.40€22.60€22.40€22.40Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:51B · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€22.51-0.734-3.2%€22.58€22.67€22.510
€23.24-0.497-2.1%€23.24€23.24€23.240
€23.74+0.124+0.5%€23.74€23.74€23.740
€23.61-0.0010.0%€23.61€23.61€23.610
€23.61+0.45+1.9%€23.43€23.80€23.410
€23.16-0.57-2.4%€23.17€23.18€22.980
€23.73+0.706+3.1%€23.73€23.73€23.730
€23.03+0.291+1.3%€23.03€23.03€23.030
€22.74-0.432-1.9%€22.74€22.74€22.740
€23.17+0.227+1.0%€23.17€23.17€23.170
€22.94+2.863+14.3%€22.94€22.94€22.940
€20.08-1.99-9.0%€22.36€22.39€20.01108
€22.07-0.533-2.4%€22.07€22.07€22.070
€22.60+2.223+10.9%€20.05€22.66€20.04172
€20.38+0.042+0.2%€20.42€20.48€20.0350
€20.34+0.448+2.3%€19.92€20.50€19.610
€19.89+1.059+5.6%€19.89€19.89€19.890
€18.83-2.061-9.9%€18.83€18.83€18.830
€20.89+0.278+1.3%€20.58€21.02€20.57200
€20.61+1.005+5.1%€20.65€20.70€20.590
€19.61+0.017+0.1%€19.61€19.61€19.610
€19.59+0.057+0.3%€19.59€19.59€19.590
€19.53+0.675+3.6%€19.53€19.53€19.530
€18.86+0.037+0.2%€18.86€18.86€18.860
€18.82-0.021-0.1%€18.79€18.83€18.770
€18.84-1.04-5.2%€18.58€18.95€18.430
€19.88-0.718-3.5%€19.88€19.88€19.880
€20.60+2.215+12.0%€18.56€20.63€18.46165
€18.39+0.125+0.7%€18.39€18.39€18.390
€18.26+0.716+4.1%€17.71€18.27€17.690
€17.54+0.48+2.8%€17.27€17.56€17.260
€17.06-0.206-1.2%€17.06€17.06€17.060
€17.27+0.12+0.7%€17.28€17.28€17.160
€17.15-0.485-2.8%€17.64€17.84€17.030
€17.64+0.563+3.3%€17.26€17.69€17.160
€17.07+0.436+2.6%€16.74€17.12€16.720
€16.64-0.146-0.9%€16.75€16.75€16.470
€16.78+0.198+1.2%€16.72€16.80€16.460
€16.58-0.303-1.8%€16.61€16.61€16.540
€16.89-0.751-4.3%€17.63€17.72€16.770
€17.64+0.546+3.2%€16.98€17.73€16.930
€17.09-1.027-5.7%€18.08€18.13€17.050
€18.12-0.793-4.2%€18.97€19.07€18.060
€18.91+0.082+0.4%€18.91€18.91€18.910
€18.83-0.182-1.0%€18.83€18.83€18.830
€19.01-0.141-0.7%€19.04€19.10€19.010
€19.15-0.013-0.1%€19.15€19.15€19.150
€19.17-0.104-0.5%€19.17€19.17€19.170
€19.27-0.117-0.6%€19.27€19.27€19.270
€19.39-0.067-0.3%€19.39€19.39€19.390
€19.45+0.266+1.4%€19.45€19.45€19.450
€19.19-0.546-2.8%€19.31€19.32€19.120
€19.73+0.177+0.9%€19.73€19.73€19.730
€19.56+0.033+0.2%€19.56€19.56€19.560
€19.52-0.12-0.6%€19.52€19.52€19.520
€19.64+1.065+5.7%€20.13€20.30€19.630
€18.58+1.02+5.8%€18.58€18.58€18.580
Ticker
Frankfurt:51B
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

All Bioventix PLC news

Bioventix PLC on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
8 in the last 12 months · 65 in all · newest Nov 6, 2026 · oldest 2010
Decks
13 decks · latest October 2026

Where Bioventix PLC is listed

ListingExchangeCountryCurrency
LSE:BVXP · Home listingLSEUnited KingdomGBX
LS Exchange:A113DDLS ExchangeGermanyEUR
Lang & Schwarz:A113DDLang & SchwarzGermanyEUR
AQUIS:BVXP.GBAQUISUnited KingdomGBX
Dusseldorf:51BDusseldorfGermanyEUR
Frankfurt:51B · This pageFrankfurtGermanyEUR
gettex:51BgettexGermanyEUR
Stuttgart:51BStuttgartGermanyEUR
OTC:BVNXFOTCUnited StatesUSD

Valuation

P/E 13.4× against a median of 35.6×: 2nd lowest of 5 Diagnostics & research services companies shown. Statements: Year to Jun 30, 2025 · balance Dec 31, 2025 · price Nov 20, 2026

Enterprise value
£96.58M GBP
P/E
13.4×
EV/sales
7.4×
EV/EBITDA
9.7×
Price/book
9.2×
Gross margin
90.9%
Operating margin
75.5%
Net margin
57.8%
Debt to equity
0.0×
Beta
No index for this market yet

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Bioventix PLC · LSE:BVXPUS$133.3MUS$126.3M13.4×7.4×9.7×9.2×57.8%0.0×n/a
Genovis AB · OMXSTO:GENOUS$150.1MUS$142.7M74.9×10.8×41.7×5.0×15.1%0.3×n/a
Genomictree, Inc. · KRX:228760US$148.6MUS$89.43Mn/a40.6×n/a1.6×−306.4%0.0×n/a
Anbio Biotechnology · NASDAQ:NNNNUS$145.7MUS$133.8M22.8×15.5×n/a4.8×74.1%0.0×0.56
MaxCyte, Inc. · NASDAQ:MXCTUS$141.5MUS$57.06Mn/a1.7×n/a0.9×−81.4%0.1×0.93
Shanghai Rightongene Biotechnology Co. Ltd. Class A · SSE:688217US$139.0MUS$102.4Mn/a4.6×n/a1.1×−43.9%0.0×n/a
EKF Diagnostics Holdings plc · LSE:EKFUS$134.4MUS$115.4M48.4×1.7×7.1×1.5×4.1%0.0×n/a
Curiosis, Inc. · KRX:494120US$131.9MUS$118.3Mn/a18.7×n/a7.1×−93.3%0.0×n/a
Bioneer Corporation · KRX:064550US$128.3MUS$107.8Mn/a0.4×10.0×0.8×−1.9%0.3×n/a
Fine Foods & Pharmaceuticals N.T.M. SpA · MIL:FFUS$123.5MUS$174.6M11.1×0.6×4.6×0.8×4.0%0.6×n/a
Burning Rock Biotech Ltd. · NASDAQ:BNRUS$116.7MUS$60.66Mn/a0.8×n/a1.6×−13.6%0.1×1.51
Median of the othersUS$136.7MUS$111.6M35.6×3.2×8.6×1.5×−7.8%0.1×0.93

Forecasts

Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
3900.00 GBX · Analysts' mean
EPS, year to Jun 2027
1.43 · 1 analyst
Revenue, year to Jun 2027
12.96M · 1 analyst

Team and board

Officers

OfficerRole
Peter HarrisonChief Executive Officer
Bruce HiscockChief Financial Officer

Board

DirectorRole
Ian NicholsonChairman and Independent Non-Executive Director
Bruce HiscockChief Financial Officer
Chris YatesIndependent Non-Executive Director
Jo PisaniIndependent Non-Executive Director
Peter HarrisonChief Executive Officer

Events

QuarterResultsShare move
Quarter to Sep 30, 2025Nov 11, 20250.0%
Q2 2025Mar 31, 2025−11.8%
Q2 2023Mar 27, 2023 · Before open+7.9%
Quarter to Sep 30, 2022Oct 24, 2022 · After close−1.5%
Q2 2022Mar 30, 2022+7.2%
Q1 2022Oct 18, 2021−0.6%
Q2 2021Mar 29, 2021+2.6%

Open Events

Decks

DeckKindSlidesDate
FY2026 Earnings PresentationEarnings26 slidesOctober 2026
Investor Presentation (March 2026)Investor deck15 slidesMar 30, 2026
Investor Presentation (October 2025)Investor deck15 slidesOct 27, 2025
Investor Presentation (March 2025)Investor deck16 slidesMar 31, 2025
Investor Presentation (October 2024)Investor deck19 slidesOct 28, 2024
Investor Presentation (March 2024)Investor deck15 slidesMar 25, 2024
Investor Presentation (October 2023)Investor deck19 slidesOct 30, 2023
Investor Presentation (March 2023)Investor deck16 slidesMar 27, 2023
Investor Presentation (March 2023)Investor deck15 slidesMar 27, 2023
Investor Presentation (October 2022)Investor deck15 slidesOct 24, 2022
All 13 decks
DeckKindSlidesDate
Investor Presentation (March 2022)Investor deck11 slidesMar 28, 2022
Investor Presentation (March 2021)Investor deck11 slidesMar 29, 2021
Investor Presentation (October 2019)Investor deck15 slidesOctober 2019

Open Decks

Financials

Annual, in GBP

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue13.1M13.6M12.8M11.7M10.9M10.3M9.29M8.75M7.25M5.52M
Cost of revenue1.20M925.5K957.6K853.8K952.6K955.4K875.1K573.2K494.9K494.9K
Gross profit11.9M12.7M11.9M10.9M9.98M9.36M8.41M8.18M6.75M5.02M
Research and development1.49M999.4K1.20M975.3K1.20M1.18M1.12M868.5K764.5K713.7K
Selling, general and administrative2.05M1.99M1.77M1.61M1.51M1.42M1.27M1.18M998.8K839.2K
Operating income9.90M10.6M10.0M9.27M8.09M7.96M7.03M6.90M5.71M4.13M
Depreciation and amortization92.8K113.6K129.2K143.4K135.1K133.6K67.5K58.5K39.5K41.7K
EBITDA10.00M10.7M10.2M9.42M8.22M8.09M7.10M6.96M5.75M4.17M
Interest expense0303263.4K243.7K0150164
Income before tax10.1M10.6M10.1M9.26M8.09M8.20M6.97M6.87M5.77M4.22M
Income tax2.51M2.48M1.74M1.60M1.39M1.00M1.10M1.20M849.6K724.5K
Net income7.58M8.10M8.37M7.67M6.73M7.20M5.86M5.66M4.92M3.49M
Earnings per share, basic1.431.531.581.461.281.381.121.080.950.68

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents5.08M6.00M5.72M6.13M6.49M8.08M6.54M6.99M6.17M5.38M
Receivables6.24M6.21M5.81M5.22M4.63M3.65M3.93M3.82M3.34M435.6K
Inventory689.4K615.3K565.4K461.8K332.5K245.4K239.3K283.1K226.2K198.9K
Current assets12.0M12.8M12.1M11.8M11.5M12.0M10.7M11.1M9.74M8.26M
Property, plant and equipment694.4K843.7K718.5K514.8K497.8K449.3K467.1K
Goodwill00
Total assets12.9M13.7M13.3M13.1M12.9M13.3M11.6M11.9M10.4M8.78M
Accounts payable77.9K170.0K77.7K157.3K150.9K96.1K25.3K20.6K23.3K22.1K
Current liabilities1.31M1.73M1.20M1.25M1.01M728.6K756.6K838.4K219.9K549.9K
Total liabilities1.31M1.73M1.22M1.30M1.09M778.9K787.4K864.7K236.1K567.9K
Shareholders' equity11.6M12.0M12.1M11.8M11.8M12.5M10.8M11.0M10.1M8.21M
Shares outstanding5.29M5.30M5.29M5.26M5.26M5.22M5.23M5.23M5.20M5.14M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations7.03M8.34M7.90M7.56M6.37M7.72M5.88M5.92M3.96M3.17M
Capital spending-19.2K-15.9K-10.6K-11.8K-260.3K-339.6K-84.5K-107.6K-21.7K-21.0K
Free cash flow7.01M8.33M7.89M7.55M6.11M7.38M5.79M5.81M3.94M3.15M
Cash from investing173.2K186.1K90.5K-11.8K-259.8K-561.3K-146.8K-169.4K-118.4K2.58K
Cash from financing-8.12M-8.25M-8.30M-7.92M-7.69M-5.62M-6.18M-4.93M-3.05M-1.92M
Dividends paid-8.19M-8.25M-8.44M-7.92M-7.71M-6.50M-6.22M-4.93M-3.37M-1.92M
Share buybacks20.2K879.7K41.0K321.1K321.1K
Change in cash-919.7K283.1K-410.8K-368.3K-1.58M1.54M-449.2K819.6K786.5K1.25M

Open Financials

Cap table

Built by 6ix from Bioventix PLC’s releases

Common shares
5,224,860
Fully diluted
5,224,860

Fully diluted

LineShares
Common shares5,224,860

Share count over time

CountShares
Nov 22, 20265,224,860

Open Cap table

Shareholders

StakeStakeSharesDateFiling
Liontrust Investment Partners LLP9.90%517KOct 29, 2026TR-1 holding notification (FCA)

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Bruce HiscockChief Financial Officer · Since at least Apr 20, 2026
Chris YatesIndependent Non-Executive Director · Since at least Feb 24, 2026
Ian NicholsonChairman and Independent Non-Executive Director · Since at least Nov 5, 2026
Jo PisaniIndependent Non-Executive Director · Since at least Nov 5, 2026
Peter HarrisonChief Executive Officer · Since at least Oct 26, 2026

Open People

Log in to ask 6ix AI your own questions about Bioventix PLC.